New York, NY (PRWEB) March 11, 2014
The prescription drug safety center DrugNews.net is announcing new information on the site about the blood thinner Pradaxa. A new report shows the Food and Drug Administration of Jordan recently approved the popular drug, marking the 100th country to authorize its use*.
DrugNews is a free resource for patients taking popular prescription drugs, providing the latest recalls, safety alerts, research and litigation news. Visitors can see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.
The blood thinner Pradaxa is prescribed to prevent blood clots and strokes in patients with atrial fibrillation. The maker of the drug, Boehringer Ingelheim, recently announced it was approved for use in its 100th country, Jordan*. Experts disagree, however, whether Pradaxa increases risks of internal bleeding.
The resource center has added a study suggesting patients taking newer blood thinners like dabigatran may be 55% more likely to suffer internal bleeding**.The Institute for Safe Medication Practices also advised internal bleeding from Pradaxa could be 5 times as likely to be fatal***. Recently, the FDA announced it would conduct a new study into Pradaxa bleeding risks****.
In the U.S., over 2,100 families have filed a Pradaxa lawsuit alleging internal bleeding, leading to the consolidation of cases in a special federal Pradaxa multidistrict litigation court*****. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugNews.net or speak with a lawyer about their legal options. Due to the specialized nature of federal drug injury cases, DrugNews only recommends lawyers who have already handled Pradaxa lawsuits.
Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.
*Boehringer Ingelheim, 3/6/14; http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/06_march_2014_dabigatranetexilate.html
**Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****Forbes, 1/3/14; forbes.com/sites/larryhusten/2014/01/03/fda-plans-new-safety-assessment-of-dabigatran-pradaxa/
*****JPML, 2/19/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-February-19-2014.pdf